

# Enrolling Research Studies

## 15 November 2017

- **Crohn's Disease/ Ulcerative Colitis Humira (AbbVie)**
- **Crohn's Disease (Eli Lilly)**
- **Ulcerative Colitis (Genentech)**
- **Crohn's Disease (Genentech)**
- **Crohn's Disease / Ulcerative Colitis (Gilead)**
- **Crohn's Disease (Takeda)**
- **Ulcerative Colitis (Pfizer)**
- **Ulcerative Colitis (Receptos)**
- **Ulcerative Colitis (Abbvie)**
- **Fistulizing Perianal Crohn's Disease (Gilead)**
- **Small Bowel Crohn's Disease (Gilead)**
- **Iron Deficiency Anemia (Shield)**
- **Crohn's Disease (Abbvie)**
- **NASH (Intercept)**
- **NASH Cirrhosis (Intercept)**
- **NASH Cirrhosis (Connatus)**
- **NAFLD (Gilead)**
- **NASH and NASH/Cirrhosis (Gilead)**
- **NASH (Proof of Concept no placebo) (Gilead)**
- **NASH (Allergan)**
- **NASH (Cirus)**
- **Gastroparesis (Allergan)**
- **Eosinophilic Esophagitis (SHIRE)**

**Coming soon:**

**Abbvie Crohn's Oral ABT 494 Bio exp./Naïve**

**Allergan Gastroparesis**

# ABBVIE Crohn's and UC

Looking for patients who would be a good Humira candidate (either anti-TNF naïve or secondary failure/intolerance to Remicade)

No need to have on Imuran.

**No PLACEBO.** Randomized to standard induction vs higher induction dose.

**Call Amanda @ 2133**

# ELI LILLY Crohn's Disease

Induction and maintenance in subjects that are biologic naïve or failures.

SubQ IL-23 antagonist

Call Michelle @ 2107

# GENENTECH UC

TNF Naïve

Very promising alpha 4-beta 7 and  
alpha E-beta 7 integrin.

Call Heather @ 2114

# GENENTECH UC

Anti TNF Failures.

Very promising alpha 4-beta 7 and  
alpha E-beta 7 integrin.

Call Heather @ 2114

# GENENTECH Crohn's Disease

Evaluate safety and efficacy of  
Etrolizumab as an induction and  
maintenance treatment for  
patients with Mod to Severely  
active Crohn's Disease

Call Heather @ 2114

# GILEAD Crohn's and UC

- **Moderately to Severely Active Crohn's Disease / Ulcerative Colitis**
- **Filgotinib (JAK inhibitor)**

**Call Maggie @ 2141**

# TAKEDA Crohn's Disease

- Mod to Severe active Crohn's disease. Must have failed tx with steroids immunosuppressants and/or anti-TNF
- Vedolizumab IV induction then SQ

Call Stephanie @ 2134



# PFIZER Ulcerative Colitis

Moderate to severe UC

Placebo Controlled

Induction and chronic therapy  
using PF-06651600 and PF-  
06700841

Call Alisha @ 2116

# RECEPTOS Ulcerative Colitis

Trial of Oral RPC 1063 as therapy for  
Moderate to Severe Ulcerative Colitis

Call Stephanie @ 2134

# ABBVIE Ulcerative Colitis

ABT-494 Induction and maintenance therapy in patient with mod to severely active UC. Must have failed corticosteroids, immunosuppressants and/or biologics

Call Michelle @ 2107

# GILEAD Perianal Fistualizing Crohn's Disease

1-3 draining perianal fistula with  
external openings of  $\geq$  4 weeks

Evaluating the safety and efficacy  
of Filgotinib (placebo controlled)

**Call Stephanie @ 2134**

# GILEAD Small Bowel Crohn's Disease

Placebo Controlled-MRI based.  
No colonoscopy required.  
Efficacy and safety study of  
Filgotinib

**Call Stephanie @ 2134**

# SHIELD Iron Deficiency Anemia

IDA in IBD patients only

Randomized controlled study with  
oral ferric maltol or IV iron ferric  
carboxy maltose

IV iron vs. novel oral formulation  
with better absorption/tolerability.

**Call Maggie @ 2141**

# GILEAD UC

Double blind study for Males  
Monitor testicular safety of  
subjects on filgotinib with  
moderate to severe UC (ages 25-  
55)

**CALL ALISHA @ 2116**

# GILEAD Crohn's Disease

Induction study to assess the efficacy and safety of Risankizumab in subjects with Moderately to severely active Crohn's disease.

2 separate studies- 1 for Biologic failure and 1 for inadequate response

**CALL MICHELLE @ 2107**



# SHIRE Ulcerative Colitis

Placebo controlled study with SHP647 (anti-MADCAM) in moderate to severe UC.

Allows mesalamine failures only.

Call Maggie@ 2141

# INTERCEPT NASH

Long term study, placebo controlled, evaluating the safety and efficacy of Obeticholic acid in subjects with NASH.

**Call Stephanie@ 2134**

# INTERCEPT NASH Cirrhosis

Placebo controlled use of Obeticholic acid in subjects with NASH compensated cirrhosis. Allows patients with burnt-out NASH.

Call Stephanie @ 2134

# CONNATUS NASH Cirrhosis

Emricasan in patients with NASH

Cirrhosis and +HPVG  $\geq$  12

Either compensated (portal hypertension) or 1 decompensation (i.e variceal bleed, ascites OR encephalopathy)

Call Heather @ 2114

# GILEAD NASH

Efficacy of Selonsertib in patients  
with F3 Nash

Liver biopsy if none  $\leq$  6 months

Call Alisha @ 2116

# GILEAD NASH/Cirrhosis

Efficacy of Selonsertib in patients  
with compensated cirrhosis

Liver biopsy if none  $\leq$  1 year

Call Alisha @ 2116

# GILEAD NASH Proof of Concept

No Placebo  
No Liver Biopsy Required  
Only MRI/MRE

**Call Michelle@ 2107**

# ALLERGAN NASH

Cenicriviroc for subjects with  
NASH. F2-F3 only.

Requires liver biopsy at screening  
(if not done in the previous 180  
days and repeat biopsy after  
treatment)

**CALL GINA @ 2141**



# CIRIUS Emminence NASH

12 month, multi dose study to evaluate safety, tolerability and efficacy of 3 dose levels of MSDC-0602K in subjects with NASH

**CALL GINA @ 2141**

# SHIRE Eosinophilic Esophagitis

Double Blind placebo controlled study to evaluate Oral Budesonide suspension in adults with EOE.

**CALL MICHELLE @ 2107**